Can ω-3 fatty acids and tocotrienol-rich vitamin E reduce symptoms of neurodevelopmental disorders?
Abstract The incidence of childhood neurodevelopmental disorders, which include autism, attention-deficit hyperactivity disorders, and apraxia, are increasing worldwide and have a profound effect on the behaviors, cognitive skills, mood, and self-esteem of these children. Although the etiologies of...
Gespeichert in:
Veröffentlicht in: | Nutrition (Burbank, Los Angeles County, Calif.) Los Angeles County, Calif.), 2014-07, Vol.30 (7), p.733-738 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 738 |
---|---|
container_issue | 7 |
container_start_page | 733 |
container_title | Nutrition (Burbank, Los Angeles County, Calif.) |
container_volume | 30 |
creator | Gumpricht, Eric, Ph.D Rockway, Susie, Ph.D, C.N.S |
description | Abstract The incidence of childhood neurodevelopmental disorders, which include autism, attention-deficit hyperactivity disorders, and apraxia, are increasing worldwide and have a profound effect on the behaviors, cognitive skills, mood, and self-esteem of these children. Although the etiologies of these disorders are unclear, they often accompany genetic and biochemical abnormalities resulting in cognitive and communication difficulties. Because cognitive and neural development require essential fatty acids (particularly long-chain ω-3 fatty acids often lacking in mother's and children's diets) during critical growth periods, the potential behavior-modifying effects of these fatty acids as “brain nutrients” has attracted considerable attention. Additionally, there is compelling evidence for increased oxidative stress, altered antioxidant defenses, and neuroinflammation in these children. The purpose of this review is to provide a scientific rationale based on cellular, experimental animal model, observational, and clinical intervention studies for incorporating the combination of ω-3 fatty acids and tocotrienol-rich vitamin E as complementary nutritional therapies in children with neurodevelopmental disorders. Should this nutritional combination correct key clinical or biochemical outcomes and/or improve behavioral patterns, it would provide a safe, complementary option for these children. |
doi_str_mv | 10.1016/j.nut.2013.11.001 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1552804048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0899900713005030</els_id><sourcerecordid>1552804048</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-ee2fad78e34ebbda30b96f0e76fbba5262e0c155692a9d70a86ab99a5ea329803</originalsourceid><addsrcrecordid>eNp9ksuqFDEQhoMonvHoA7iRbAQ33VY6fUkQPMhwvMABF-o6pJNqzNidjEl6YB7Bp_OVzDCjggtXtfn-v4qPIuQpg5oB61_uar_mugHGa8ZqAHaPbJgYeMWatr1PNiCkrCTAcEUepbSDQshePiRXTdtzxkW7IXarPf35o-J00jkfqTbOJqq9pTmYkKNDH-YqOvOVHlzWi_P0lka0q0Gajss-hyXRMFGPawwWDziH_YI-65lal0K0GNPNY_Jg0nPCJ5d5Tb68vf28fV_dfXz3YfvmrjIdiFwhNpO2g0De4jhazWGU_QQ49NM46q7pGwTDuq6XjZZ2AC16PUqpO9S8kQL4NXlx7t3H8H3FlNXiksF51h7DmlTJNgJaaEVB2Rk1MaQUcVL76BYdj4qBOslVO1XkqpNcxZgq6krm2aV-HRe0fxK_bRbg-QXQyeh5itobl_5yoh8G3srCvTpzWGQcHEaVTBFt0LqIJisb3H_PeP1P2szOu7LwGx4x7cIafbGsmEqNAvXp9AWnJ2AcoAMO_Bc_Iq3K</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552804048</pqid></control><display><type>article</type><title>Can ω-3 fatty acids and tocotrienol-rich vitamin E reduce symptoms of neurodevelopmental disorders?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Gumpricht, Eric, Ph.D ; Rockway, Susie, Ph.D, C.N.S</creator><creatorcontrib>Gumpricht, Eric, Ph.D ; Rockway, Susie, Ph.D, C.N.S</creatorcontrib><description>Abstract The incidence of childhood neurodevelopmental disorders, which include autism, attention-deficit hyperactivity disorders, and apraxia, are increasing worldwide and have a profound effect on the behaviors, cognitive skills, mood, and self-esteem of these children. Although the etiologies of these disorders are unclear, they often accompany genetic and biochemical abnormalities resulting in cognitive and communication difficulties. Because cognitive and neural development require essential fatty acids (particularly long-chain ω-3 fatty acids often lacking in mother's and children's diets) during critical growth periods, the potential behavior-modifying effects of these fatty acids as “brain nutrients” has attracted considerable attention. Additionally, there is compelling evidence for increased oxidative stress, altered antioxidant defenses, and neuroinflammation in these children. The purpose of this review is to provide a scientific rationale based on cellular, experimental animal model, observational, and clinical intervention studies for incorporating the combination of ω-3 fatty acids and tocotrienol-rich vitamin E as complementary nutritional therapies in children with neurodevelopmental disorders. Should this nutritional combination correct key clinical or biochemical outcomes and/or improve behavioral patterns, it would provide a safe, complementary option for these children.</description><identifier>ISSN: 0899-9007</identifier><identifier>EISSN: 1873-1244</identifier><identifier>DOI: 10.1016/j.nut.2013.11.001</identifier><identifier>PMID: 24631384</identifier><identifier>CODEN: NUTRER</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Animals ; Anti-Inflammatory Agents - pharmacology ; Anti-Inflammatory Agents - therapeutic use ; Antioxidants - pharmacology ; Antioxidants - therapeutic use ; Apraxia ; Apraxias - complications ; Apraxias - drug therapy ; Attention Deficit Disorder with Hyperactivity - complications ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention-deficit hyperactivity disorder ; Autism ; Autistic Disorder - complications ; Autistic Disorder - drug therapy ; Biological and medical sciences ; Brain - drug effects ; Child clinical studies ; Children ; Developmental disorders ; Diet ; Dietary Supplements ; Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes ; Fatty Acids, Omega-3 - metabolism ; Fatty Acids, Omega-3 - pharmacology ; Fatty Acids, Omega-3 - therapeutic use ; Feeding. Feeding behavior ; Fundamental and applied biological sciences. Psychology ; Gastroenterology and Hepatology ; Humans ; Infantile autism ; Medical sciences ; Nervous system (semeiology, syndromes) ; Neurodevelopmental disorders ; Neurology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Tocotrienols ; Tocotrienols - pharmacology ; Tocotrienols - therapeutic use ; Vertebrates: anatomy and physiology, studies on body, several organs or systems ; Vitamin E ; Vitamin E - metabolism ; Vitamin E - pharmacology ; Vitamin E - therapeutic use ; ω-3 fatty acids</subject><ispartof>Nutrition (Burbank, Los Angeles County, Calif.), 2014-07, Vol.30 (7), p.733-738</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-ee2fad78e34ebbda30b96f0e76fbba5262e0c155692a9d70a86ab99a5ea329803</citedby><cites>FETCH-LOGICAL-c508t-ee2fad78e34ebbda30b96f0e76fbba5262e0c155692a9d70a86ab99a5ea329803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.nut.2013.11.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64387</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28677349$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24631384$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gumpricht, Eric, Ph.D</creatorcontrib><creatorcontrib>Rockway, Susie, Ph.D, C.N.S</creatorcontrib><title>Can ω-3 fatty acids and tocotrienol-rich vitamin E reduce symptoms of neurodevelopmental disorders?</title><title>Nutrition (Burbank, Los Angeles County, Calif.)</title><addtitle>Nutrition</addtitle><description>Abstract The incidence of childhood neurodevelopmental disorders, which include autism, attention-deficit hyperactivity disorders, and apraxia, are increasing worldwide and have a profound effect on the behaviors, cognitive skills, mood, and self-esteem of these children. Although the etiologies of these disorders are unclear, they often accompany genetic and biochemical abnormalities resulting in cognitive and communication difficulties. Because cognitive and neural development require essential fatty acids (particularly long-chain ω-3 fatty acids often lacking in mother's and children's diets) during critical growth periods, the potential behavior-modifying effects of these fatty acids as “brain nutrients” has attracted considerable attention. Additionally, there is compelling evidence for increased oxidative stress, altered antioxidant defenses, and neuroinflammation in these children. The purpose of this review is to provide a scientific rationale based on cellular, experimental animal model, observational, and clinical intervention studies for incorporating the combination of ω-3 fatty acids and tocotrienol-rich vitamin E as complementary nutritional therapies in children with neurodevelopmental disorders. Should this nutritional combination correct key clinical or biochemical outcomes and/or improve behavioral patterns, it would provide a safe, complementary option for these children.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antioxidants - pharmacology</subject><subject>Antioxidants - therapeutic use</subject><subject>Apraxia</subject><subject>Apraxias - complications</subject><subject>Apraxias - drug therapy</subject><subject>Attention Deficit Disorder with Hyperactivity - complications</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention-deficit hyperactivity disorder</subject><subject>Autism</subject><subject>Autistic Disorder - complications</subject><subject>Autistic Disorder - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Child clinical studies</subject><subject>Children</subject><subject>Developmental disorders</subject><subject>Diet</subject><subject>Dietary Supplements</subject><subject>Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes</subject><subject>Fatty Acids, Omega-3 - metabolism</subject><subject>Fatty Acids, Omega-3 - pharmacology</subject><subject>Fatty Acids, Omega-3 - therapeutic use</subject><subject>Feeding. Feeding behavior</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gastroenterology and Hepatology</subject><subject>Humans</subject><subject>Infantile autism</subject><subject>Medical sciences</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurodevelopmental disorders</subject><subject>Neurology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Tocotrienols</subject><subject>Tocotrienols - pharmacology</subject><subject>Tocotrienols - therapeutic use</subject><subject>Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><subject>Vitamin E</subject><subject>Vitamin E - metabolism</subject><subject>Vitamin E - pharmacology</subject><subject>Vitamin E - therapeutic use</subject><subject>ω-3 fatty acids</subject><issn>0899-9007</issn><issn>1873-1244</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ksuqFDEQhoMonvHoA7iRbAQ33VY6fUkQPMhwvMABF-o6pJNqzNidjEl6YB7Bp_OVzDCjggtXtfn-v4qPIuQpg5oB61_uar_mugHGa8ZqAHaPbJgYeMWatr1PNiCkrCTAcEUepbSDQshePiRXTdtzxkW7IXarPf35o-J00jkfqTbOJqq9pTmYkKNDH-YqOvOVHlzWi_P0lka0q0Gajss-hyXRMFGPawwWDziH_YI-65lal0K0GNPNY_Jg0nPCJ5d5Tb68vf28fV_dfXz3YfvmrjIdiFwhNpO2g0De4jhazWGU_QQ49NM46q7pGwTDuq6XjZZ2AC16PUqpO9S8kQL4NXlx7t3H8H3FlNXiksF51h7DmlTJNgJaaEVB2Rk1MaQUcVL76BYdj4qBOslVO1XkqpNcxZgq6krm2aV-HRe0fxK_bRbg-QXQyeh5itobl_5yoh8G3srCvTpzWGQcHEaVTBFt0LqIJisb3H_PeP1P2szOu7LwGx4x7cIafbGsmEqNAvXp9AWnJ2AcoAMO_Bc_Iq3K</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Gumpricht, Eric, Ph.D</creator><creator>Rockway, Susie, Ph.D, C.N.S</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140701</creationdate><title>Can ω-3 fatty acids and tocotrienol-rich vitamin E reduce symptoms of neurodevelopmental disorders?</title><author>Gumpricht, Eric, Ph.D ; Rockway, Susie, Ph.D, C.N.S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-ee2fad78e34ebbda30b96f0e76fbba5262e0c155692a9d70a86ab99a5ea329803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antioxidants - pharmacology</topic><topic>Antioxidants - therapeutic use</topic><topic>Apraxia</topic><topic>Apraxias - complications</topic><topic>Apraxias - drug therapy</topic><topic>Attention Deficit Disorder with Hyperactivity - complications</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention-deficit hyperactivity disorder</topic><topic>Autism</topic><topic>Autistic Disorder - complications</topic><topic>Autistic Disorder - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Child clinical studies</topic><topic>Children</topic><topic>Developmental disorders</topic><topic>Diet</topic><topic>Dietary Supplements</topic><topic>Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes</topic><topic>Fatty Acids, Omega-3 - metabolism</topic><topic>Fatty Acids, Omega-3 - pharmacology</topic><topic>Fatty Acids, Omega-3 - therapeutic use</topic><topic>Feeding. Feeding behavior</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gastroenterology and Hepatology</topic><topic>Humans</topic><topic>Infantile autism</topic><topic>Medical sciences</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurodevelopmental disorders</topic><topic>Neurology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Tocotrienols</topic><topic>Tocotrienols - pharmacology</topic><topic>Tocotrienols - therapeutic use</topic><topic>Vertebrates: anatomy and physiology, studies on body, several organs or systems</topic><topic>Vitamin E</topic><topic>Vitamin E - metabolism</topic><topic>Vitamin E - pharmacology</topic><topic>Vitamin E - therapeutic use</topic><topic>ω-3 fatty acids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gumpricht, Eric, Ph.D</creatorcontrib><creatorcontrib>Rockway, Susie, Ph.D, C.N.S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nutrition (Burbank, Los Angeles County, Calif.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gumpricht, Eric, Ph.D</au><au>Rockway, Susie, Ph.D, C.N.S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can ω-3 fatty acids and tocotrienol-rich vitamin E reduce symptoms of neurodevelopmental disorders?</atitle><jtitle>Nutrition (Burbank, Los Angeles County, Calif.)</jtitle><addtitle>Nutrition</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>30</volume><issue>7</issue><spage>733</spage><epage>738</epage><pages>733-738</pages><issn>0899-9007</issn><eissn>1873-1244</eissn><coden>NUTRER</coden><abstract>Abstract The incidence of childhood neurodevelopmental disorders, which include autism, attention-deficit hyperactivity disorders, and apraxia, are increasing worldwide and have a profound effect on the behaviors, cognitive skills, mood, and self-esteem of these children. Although the etiologies of these disorders are unclear, they often accompany genetic and biochemical abnormalities resulting in cognitive and communication difficulties. Because cognitive and neural development require essential fatty acids (particularly long-chain ω-3 fatty acids often lacking in mother's and children's diets) during critical growth periods, the potential behavior-modifying effects of these fatty acids as “brain nutrients” has attracted considerable attention. Additionally, there is compelling evidence for increased oxidative stress, altered antioxidant defenses, and neuroinflammation in these children. The purpose of this review is to provide a scientific rationale based on cellular, experimental animal model, observational, and clinical intervention studies for incorporating the combination of ω-3 fatty acids and tocotrienol-rich vitamin E as complementary nutritional therapies in children with neurodevelopmental disorders. Should this nutritional combination correct key clinical or biochemical outcomes and/or improve behavioral patterns, it would provide a safe, complementary option for these children.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>24631384</pmid><doi>10.1016/j.nut.2013.11.001</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0899-9007 |
ispartof | Nutrition (Burbank, Los Angeles County, Calif.), 2014-07, Vol.30 (7), p.733-738 |
issn | 0899-9007 1873-1244 |
language | eng |
recordid | cdi_proquest_miscellaneous_1552804048 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
subjects | Animals Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Antioxidants - pharmacology Antioxidants - therapeutic use Apraxia Apraxias - complications Apraxias - drug therapy Attention Deficit Disorder with Hyperactivity - complications Attention Deficit Disorder with Hyperactivity - drug therapy Attention-deficit hyperactivity disorder Autism Autistic Disorder - complications Autistic Disorder - drug therapy Biological and medical sciences Brain - drug effects Child clinical studies Children Developmental disorders Diet Dietary Supplements Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes Fatty Acids, Omega-3 - metabolism Fatty Acids, Omega-3 - pharmacology Fatty Acids, Omega-3 - therapeutic use Feeding. Feeding behavior Fundamental and applied biological sciences. Psychology Gastroenterology and Hepatology Humans Infantile autism Medical sciences Nervous system (semeiology, syndromes) Neurodevelopmental disorders Neurology Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Tocotrienols Tocotrienols - pharmacology Tocotrienols - therapeutic use Vertebrates: anatomy and physiology, studies on body, several organs or systems Vitamin E Vitamin E - metabolism Vitamin E - pharmacology Vitamin E - therapeutic use ω-3 fatty acids |
title | Can ω-3 fatty acids and tocotrienol-rich vitamin E reduce symptoms of neurodevelopmental disorders? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A22%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20%CF%89-3%20fatty%20acids%20and%20tocotrienol-rich%20vitamin%20E%20reduce%20symptoms%20of%20neurodevelopmental%20disorders?&rft.jtitle=Nutrition%20(Burbank,%20Los%20Angeles%20County,%20Calif.)&rft.au=Gumpricht,%20Eric,%20Ph.D&rft.date=2014-07-01&rft.volume=30&rft.issue=7&rft.spage=733&rft.epage=738&rft.pages=733-738&rft.issn=0899-9007&rft.eissn=1873-1244&rft.coden=NUTRER&rft_id=info:doi/10.1016/j.nut.2013.11.001&rft_dat=%3Cproquest_cross%3E1552804048%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552804048&rft_id=info:pmid/24631384&rft_els_id=S0899900713005030&rfr_iscdi=true |